Alaunos Therapeutics, Inc. (TCRT) Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. Additionally, they are advancing hunTR, a platform focused on human neoantigen T-cell receptors, and mbIL-15, intended for solid tumor treatment. The company maintains strategic collaborations, including a licensing agreement with PGEN Therapeutics, Inc., a research and development partnership with The University of Texas MD Anderson Cancer Center, and both a patent licensing and R&D agreement with the National Cancer Institute. Previously known as ZIOPHARM Oncology, Inc., the company adopted its current name, Alaunos Therapeutics, Inc., in January 2022. Its headquarters are located in Houston, Texas.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Alaunos Therapeutics, Inc. NASDAQ:TCRT Healthcare · Biotechnology
Mkt Cap $7.22M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release ● Major ⚠ 4
Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics
Alaunos Therapeutics completed its acquisition of Velaris Therapeutics, a privately-held biotech with a PAH pipeline of ActRII-Fc ligand traps (VLR199, VLR247, VLR258) and the anti-PDGF-B antibody VLR360.
A concurrent, oversubscribed $350 million private placement led by Fairmount gives the company runway into 2029, funding proof-of-concept data for VLR199 and VLR360 and initial regulatory filings for VLR247 and VLR258, with VLR199 proof-of-concept expected in 2028.
After stockholder approval of the preferred-to-common conversion, Fairmount designees will control 4 of 5 board seats — a decisive shift in control — and pro forma shares outstanding will be roughly 358.59 million, implying meaningful dilution.
• 19d ago AI analysis › Press Release ⚠ 2
Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc.
Alaunos Therapeutics (NASDAQ: TCRT) completed its acquisition of Velaris Therapeutics, a privately held biotech developing ActRII-Fc ligand traps and complementary biologics for pulmonary arterial hypertension and related cardiopulmonary diseases.
Velaris' pipeline includes VLR199, VLR247, VLR258 and the anti-PDGF-B antibody VLR360, all discovered by Paragon Labs; the acquisition is the first company build supported by Paragon's newly expanded leadership team of former Apogee executives.
No deal consideration or terms were disclosed in the release; additional information is in Alaunos' Form 8-K filed with the SEC on October 13, 2026.
The release also highlights Paragon's track record — its assets have seeded nine companies including Apogee, which AbbVie acquired for over $10.9 billion in 2026.
• 19d ago AI analysis › Press Release ⚠ 3
Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules
Alaunos Therapeutics priced a registered direct offering of 380,469 common shares plus pre-funded warrants on up to 386,654 additional shares at $1.46 per share, for aggregate gross proceeds of approximately $1.12 million.
The deal was priced at-the-market under Nasdaq rules with Dawson James Securities as sole placement agent and is expected to close on or about September 21, 2026, off an effective Form S-3 shelf.
Proceeds are earmarked for general working capital and corporate purposes — a small but dilutive raise that underscores the micro-cap biotech's ongoing cash needs as it advances its oral obesity candidate ALN1003.
• 1mo ago AI analysis › Press Release ⚠ 3
Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study
Alaunos Therapeutics announced new preclinical data for its metabolic candidate ALN1003, showing lower liver weight in diet-induced obese mice after adjustment for body fat percentage.
The statistical analysis confirmed the findings with high significance (p=0.000005) and aligned with previous reductions in liver injury enzymes and HOMA-IR biomarkers.
The company disclosed a cash position of approximately $354,000 as of March 31, 2026, noting it intends to pursue additional financing to support operations.
• 4mo ago AI analysis › Press Release ⚠ 3
Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies
Alaunos Therapeutics reported integrated preclinical data for ALN1003, showing broad metabolic improvements in diet-induced obese mice, including up to 30.5% body weight loss and 43% liver weight reduction.
The data comes from two non-GLP mouse studies. The CEO cautioned that these are early findings that must be interpreted with care and do not guarantee human efficacy.
The company disclosed a cash balance of only $0.354 million as of March 31, with a runway extending into the second quarter of 2026, signaling an urgent need for additional financing.
• 5mo ago AI analysis › Press Release ⚠ 3
Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models
Alaunos Therapeutics released preclinical data for ALN1003 showing improved insulin-resistance biomarkers and reduced liver steatosis in diet-induced obesity mouse models.
The data supports the company’s thesis that ALN1003 engages multiple metabolic axes, including adipose endocrine signaling and hepatic lipid accumulation, beyond simple weight loss.
However, the company disclosed only $0.35 million in cash with a runway extending into Q2 2026, signaling an urgent need for financing to continue operations and advance the program.
• 5mo ago AI analysis › Press Release
Valion Bio Appoints Melinda Lackey as General Counsel
Alaunos Therapeutics (TCRT) has lost Melinda Lackey, its Senior Vice President of Legal & Administration, who has joined Valion Bio, Inc. as General Counsel.
During her tenure at Alaunos, Lackey managed all legal and compliance functions for the publicly traded immunology company, overseeing regulatory strategy and capital markets obligations.
Her departure creates a vacancy in Alaunos' senior legal leadership as she moves to support Valion Bio's capital raise and clinical development initiatives.
• 5mo ago AI analysis › 
